Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable promise, offering new opportunities for targeted treatment and flexible manufacturing, as was recently demonstrated by the rapid development of mRNA-based COVID -19 vaccines. In recent years, we at Lonza have amassed considerable expertise in the commercial manufacturing of mRNA and its encapsulation in Lipid Nanoparticles (LNP) at cGMP quality.
You may also be interested in:
mRNA
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
Building momemtum_QA_DEC24
Article
Expert Q&A: Partnering for Success in the Supplement Market
Explore how Lonza's innovative platform and visionary approach to partnership empower brands with a...
AI-Enabled Route Scouting Service Scientists
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
Developing innovative medicines often involves intricate small-molecule APIs with lengthy synthetic...
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
capsule image
White paper
Bridging the Gaps in Oral Dosage Research: 4 Focus Areas Highlighted by the UNGAP network
As our designated center of excellence for novel drug delivery systems, Innovaform™ Accelerator is...
Video
CAR-T Cells on the Fast Lane: From T-cell Selection to CAR-T Cell Drug Product in Just 3 Days
In this presentation, we explore the rapid growth of the CAR T market, driven by oncology...
Used as thumbnail for Powder to Particles podcast.
White paper
Unlocking the Potential of Carrier-Based Formulations: A Process Optimization Guide
Carrier-based formulations are commonly used in drug delivery systems, particularly in inhalation...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
Used as thumbnail for Powder to Particles podcast.
Video
Small Molecule API & HPAPI Development Capacity
This video presents Lonza's capabilities, facility locations, and timelines to assist biopharma...